Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Clinical and Molecular Hepatology. 2023;29(2):510-512 
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Clinical and Molecular Hepatology. 2023;29(2):513-515
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Clinical and Molecular Hepatology. 2023;29(2):482-495
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B
Alimentary Pharmacology & Therapeutics. 2020;52(5):911-912
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors’ reply
Alimentary Pharmacology & Therapeutics. 2020;52(5):913-914
Clinical, serological and histologic follow-up of chronic HBV and HDV hepatitis
Journal of Hepatology. 1987;5:S136
Long-term histologic outcome of chronic posttransfusion NANB hepatitis evaluated by a scoring system
Journal of Hepatology. 1990;11:S161
Change of the host immune response during the early phase of interferon therapy correlates with its long-term efficacy for chronic hepatitis C
Hepatology Research. 2001;19(2):131-143
Potential treatment for chronic hepatitis B carriers at immune tolerant phase
Focus on Alternative and Complementary Therapies. 2014;19(2):96-97
Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study
Hepatology. 2003;38(2):493-502